Načítá se...
MON-130 Optimal Glycemic Control in a Patient with HNF1A MODY with GLP1-RA Monotherapy: Implications for Future Therapy
Background: Among those diagnosed with maturity-onset diabetes of the young (MODY), the most common form is hepatocyte nuclear factor 1α MODY (HNF1A MODY). Individuals with HNF1A MODY typically respond very well to treatment with sulfonylureas (SU) which are recommended as first line therapy. Clinic...
Uloženo v:
| Vydáno v: | J Endocr Soc |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Endocrine Society
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6551179/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-MON-130 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|